Dirk Schadendorf

Workplace: Germany, Essen, Essen University Hospital
Prof. Dirk Schadendorf specializes in melanoma with of experience, including groundbreaking research on tumor immunology.
- Fellowship at Cornell Medical Center
- Recipient of AVON Award for breast cancer research
- Published key papers on melanoma immunotherapy
- Expert in tumor-associated antigen research

Doctor's services

How are we doing?

1 of 3

Information about this doctor is full and clear

Strongly disagree

Strongly agree

Qualifications

Prof. Dirk Jager is a medical oncologist who treats hematologic and oncological conditions at Essen University Hospital. He holds a Hirsch index of 70 for his scientific contributions. He treats various cancers using modern protocols for melanoma and gastrointestinal tumors.

Clinical Specialization

Dr. Jager treats cancers and blood disorders. He applies therapies for patients with advanced malignancies. These protocols help treat melanoma and gastrointestinal tumors. He manages the following conditions:

Lymphomas
Acute Leukemia
Multiple Myeloma
Breast Cancer
Melanoma

He performs procedures such as bone marrow transplants and immunotherapy. Dr. Jager also provides specialized diagnostics. These include biopsies of the breast, liver, lungs, and pancreas.

Education and Academic Training

1998 – Fellowship at Cornell Medical Center, New York, USA
1998 – Rose-Marie-Finnell Memorial Fellowship for Breast Cancer Research

Awards and Recognition

The doctor has received honors for his research in oncology.

2001 – AVON Award for breast cancer research, Cancer Research Institute
2006 – Investigators Award, Cancer Research Institute

Research and Publications

Prof. Jager has authored over 400 scientific works. His research explores how to trigger the immune system to fight tumor cells. He has published findings on the following topics:

Tumoral immune cell exploitation in colorectal cancer liver metastases
Prognostic Significance of Spontaneous Antibody Responses in Malignant Melanoma Patients
Anticancer immunotherapy by CTLA-4 blockade
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody
Low-dose irradiation programs macrophage differentiation